By Ruchika Sharma
Copyright medicaldialogues
Noida: Jubilant Pharmova has announced the appointment of Arun Kumar Sharma as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from October 1, 2025.He shall hold the CFO office for an interim period till the appointment of new CFO.”we wish to inform that the Board of Directors of the Company, at its meeting held on September 23, 2025, on the recommendation of Nomination, Remuneration and Compensation Committee and the Audit Committee, had considered and approved the appointment of Mr. Arun Kumar Sharma as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from October 1, 2025,” the company stated in a BSE filing.”The appointment is made for an interim period to ensure a smooth transition to the new Chief Financial Officer, for which the identification and appointment process is in progress,” it added.Arun Kumar Sharma is a strategic and result-driven financial company with over three decades of progressive experience across corporate finance, global treasury, investor relations, risk management, financial restructuring, insurance, capex control, and business transformation. He has consistently demonstrated excellence in driving sustainable growth, enhancing shareholder value, and upholding governance standards in large listed companies. He has held various positions in Jubilant Bhartia Group including CFO role in Jubilant Pharma Holdings Inc. USA for approx. 4 years, Jubilant Lifesciences Limited (Chemical Business) for approx. 3 years and Jubilant Pharmova Limited for approx. 2 years (April’ 2021-May’2023).Read also: Jubilant Ingrevia appoints Sonia Dharap as Vice President – Sales, Business Development (US)Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses.Read also: Jubilant Pharmova to sell, transfer API business to wholly owned arm
